Project Grant K01HL177339
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $419,056 to Texas A&M AgriLife Research to develop nanoparticle-based therapies to improve mitochondrial function and treat metabolic disease in post-menopausal women. The research aims to determine if two distinct nanoparticles - molybdenum disulfide (MoS2) nanoflowers and mitochondria-targeted estradiol (Mito-E2) - can enhance mitochondrial function and reduce oxidative stress in...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $162,384 Project Grant to Dr. Ester Oh at the University of Colorado-Denver. The grant will fund research to evaluate the efficacy and mechanisms of equol supplementation for improving vascular function in postmenopausal women with chronic kidney disease (CKD). The research aims to advance understanding of sex-specific cardiovascular disease risk factors and...
- This Project Grant award for $2,398,590.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of brain microcirculation and capillary endothelial cell energetics in the development of vascular cognitive impairment and dementia (VCID) observed in Alzheimer's disease (AD) and AD-related dementias. The...
- This Project Grant award for $470,786, issued on May 15, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the relationship between aging, immune function, and mitochondrial dysfunction in the pathogenesis of vascular cognitive impairment...
- This federal Project Grant award of $163,145.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate sex differences in cardiac macrophages and their role in right ventricular function in pulmonary arterial hypertension (PAH). The University of Colorado-Denver, the awardee, will conduct this research with the goal of understanding how female sex hormones regulate gene expression in right ventricular macrophages and...
- This federal Project Grant award of $198,549.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to determine the contribution of HIV and menopausal phase to cardiovascular disease (CVD) risk parameters and subclinical atherosclerosis in women with HIV. The study aims to (1) assess the association of HIV and menopausal phase with CVD risk factors, (2) evaluate the relationship between HIV, menopausal phase, immune...
- This federal Project Grant award of $429,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a study to investigate the impact of selective vagal neuromodulation on heart failure indices. The 2-year project, with a start date of September 1, 2025, will be conducted by the University of Colorado-Denver. The research aims to better understand the neural interface by studying the effects of selective activation of cholinergic (efferent)...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $720,399 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Colorado-Denver. The 5-year project, running from Sep 1, 2025 to May 31, 2030, will investigate the associations between maternal microbiomes, metabolomes, and cardiovascular health outcomes in a racially and ethnically diverse pregnancy cohort. Key objectives are to characterize...
- This federal Project Grant award of $727,080 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the neurogenic mechanisms underlying psychosocial stress-induced cardiovascular disease and postpartum depression. The primary research objective is to delineate how stress-evoked mitochondrial dysfunction in the medial prefrontal cortex contributes to postpartum cardiovascular and behavioral changes. The 4-year project,...
- This federal Cooperative Agreement award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $748,751 award, effective September 15, 2025 through May 31, 2030, will support the "Microvascular Aging Effects - Women's Evaluation of Systemic Aging Tenacity in Heart, Brain and Frailty (MAE-WEST HBF)" research project conducted by the Cedars-Sinai Medical Center. The research aims to investigate how small vessel...
The University of Colorado has been awarded a $184,464 Project Grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the efficacy of a mitochondrial-targeted antioxidant (MitoQ) for improving cerebrovascular function in postmenopausal women. The principal investigator, Dr. Kevin O. Murray, a postdoctoral fellow at the University of Colorado, aims to determine if MitoQ treatment can help mitigate the detrimental effects of estrogen deficiency on cerebrovascular function in postmenopausal women. The project, scheduled to run from Sep 24, 2025 to Aug 31, 2030, will also involve Dr. Murray acquiring new skills to assess cerebrovascular function and developing his professional research and management capabilities under the mentorship of established NIH-funded investigators.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $184.5k | 9/22/25 |